A comprehensive view of Phase 1 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer and BioNTech move T-cell enhancing COVID-19 vaccine into phase 1 clinical trial; candidate targets highly conserved non-spike proteins to boost, broaden T-cell response, provide memory T-cell persistence, enhance B-cell response durability

Decibel Therapeutics initiates Phase 1-2 clinical trial of DB-OTO gene therapy developed with Regeneron intended to provide hearing to patients with congenital hearing loss due to otoferlin deficiency; trial to involve pediatric patients

AstraZeneca’s COVID-19 nasal vaccine candidate fails to produce strong immune response in small Phase 1 trial at Oxford University; test vaccine is spray version of AstraZeneca’s Vaxzevria COVID-19 shot

After $100M deal with MeiraGTx, J&J links gene therapy to improved vision in early-phase trial; after 12 months, 48% of participants on low/intermediate doses of X-linked retinitis pigmentosa candidate met responder endpoint

Regeneron and partner Alnylam Pharmaceuticals to move into Phase 2 trials with their experimental injectable liver disease drug ALN-HSD to treat nonalcoholic steatohepatitis after encouraging Phase 1 findings

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count